B+
Bull case
25%
Probability
Target price
$5.72
+46.3% vs current
OBIO
Orchestra BioMedDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$4.40
+12.5% vs current
B-
Bear case
25%
Probability
Target price
$3.30
-15.6% vs current
AI sentiment snapshot
Latest data as of 2025-12-07
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+63.0
Score
AI commentary
Market commentary is mixed: some investors focus on upside from potential partnerships and clinical readouts, while others emphasize financing risk and binary clinical outcomes [#PR-Partner], [#10Q-2025Q3]. Recent newsflow has been limited, producing muted trading volumes and divergent short‑term views [#News-Week]. Overall tone is cautiously neutral-to-cautious ahead of upcoming milestones [#AnalystNote].
RankAlpha Sentiment AI - 2025-12-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-catalystPartnership or licensing dealHigh impact
A strategic licensing or partnership with a larger medtech/biotech player would validate technology and reduce execution risk [#PR-Partner].
2026-01-31catalystEquity financing / dilutionHigh impact
Need for near-term capital could lead to equity raises and downward pressure on the share price if terms are unfavorable [#10Q-2025Q3].
2026-03-31eventClinical readout for lead programHigh impact
Top-line efficacy/safety data from the company's lead clinical program could re-rate valuation if results beat or miss expectations [#PR-Clinical].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-07 • Updated nightlySource: Internal modelMethodology